Adam has a broad background in the pharmaceutical and biotechnology industries. He is a business developer and marketer with direct experience of drug and device development and the capital markets. Previously, as Chief Business Officer at PowderMed, he led business development and commercial strategy which culminated in the successful sale of the. company to Pfizer in late 2006, two and a half years after a series ‘A’ venture funding round. Adam is also a Director at MGB Biopharma, another Archangels backed company in Scotland, focused on a new class of antibacterial drugs. His earlier career included roles in business development, marketing and R&D at PPL Therapeutics, GlaxoSmithKline, Abbott Laboratories and Schering AG, and as a City analyst at ABN Amro Hoare Govett. His educational background includes a BSc in Pharmacology from Southampton University and an MBA from Warwick Business School.
